Literature DB >> 17360080

A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity.

Ricardo Carrion1, Jean L Patterson, Curtis Johnson, Monica Gonzales, Carmen R Moreira, Anysha Ticer, Kathleen Brasky, Gene B Hubbard, Dmitry Moshkoff, Juan Zapata, Maria S Salvato, Igor S Lukashevich.   

Abstract

Lassa virus (LASV) is responsible for the deaths of thousands of people in West Africa annually. Genetic diversity among LASV strains is the highest among the Arenaviridae and represents a great challenge for vaccine development. Guinea pigs vaccinated with a ML29 reassortant vaccine experienced sterilizing immunity and complete protection when challenged on day 30 either with homologous virus or with the distantly related Nigerian isolate. Simultaneous vaccination-challenge or challenge on day 2 after vaccination also protected 60-100% of the animals against both strains, but without sterilizing immunity. These results indicate that simultaneous replication of ML29 and LASV attenuates the virulence of LASV infection.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17360080      PMCID： PMC1892204          DOI： 10.1016/j.vaccine.2007.02.038

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  73 in total

1.  Evidence of segment reassortment in Crimean-Congo haemorrhagic fever virus.

Authors:  Roger Hewson; Anatoly Gmyl; Larissa Gmyl; Svetlana E Smirnova; Galina Karganova; Bushra Jamil; Rumina Hasan; John Chamberlain; Christopher Clegg
Journal:  J Gen Virol       Date:  2004-10       Impact factor: 3.891

2.  The Lassa fever virus L gene: nucleotide sequence, comparison, and precipitation of a predicted 250 kDa protein with monospecific antiserum.

Authors:  I S Lukashevich; M Djavani; K Shapiro; A Sanchez; E Ravkov; S T Nichol; M S Salvato
Journal:  J Gen Virol       Date:  1997-03       Impact factor: 3.891

3.  Phylogenetic analysis of the Arenaviridae: patterns of virus evolution and evidence for cospeciation between arenaviruses and their rodent hosts.

Authors:  M D Bowen; C J Peters; S T Nichol
Journal:  Mol Phylogenet Evol       Date:  1997-12       Impact factor: 4.286

4.  Characterization of arenaviruses using a family-specific primer set for RT-PCR amplification and RFLP analysis. Its potential use for detection of uncharacterized arenaviruses.

Authors:  M E Lozano; D M Posik; C G Albariño; G Schujman; P D Ghiringhelli; G Calderón; M Sabattini; V Romanowski
Journal:  Virus Res       Date:  1997-05       Impact factor: 3.303

5.  Hunting of peridomestic rodents and consumption of their meat as possible risk factors for rodent-to-human transmission of Lassa virus in the Republic of Guinea.

Authors:  J Ter Meulen; I Lukashevich; K Sidibe; A Inapogui; M Marx; A Dorlemann; M L Yansane; K Koulemou; J Chang-Claude; H Schmitz
Journal:  Am J Trop Med Hyg       Date:  1996-12       Impact factor: 2.345

6.  Completion of the Lassa fever virus sequence and identification of a RING finger open reading frame at the L RNA 5' End.

Authors:  M Djavani; I S Lukashevich; A Sanchez; S T Nichol; M S Salvato
Journal:  Virology       Date:  1997-09-01       Impact factor: 3.616

7.  Early diagnosis of Lassa fever by reverse transcription-PCR.

Authors:  A H Demby; J Chamberlain; D W Brown; C S Clegg
Journal:  J Clin Microbiol       Date:  1994-12       Impact factor: 5.948

8.  [Activity of lymphocytic choriomeningitis virus (LCM) in the endemic area of Argentine hemorrhagic fever (AHF). I. Serological studies in rodents captured in the City of Pergamino].

Authors:  J I Maiztegui; M S Sabattini; J G Barrera Oro
Journal:  Medicina (B Aires)       Date:  1972 Mar-Apr       Impact factor: 0.653

9.  Resistance of lymphocytic choriomeningitis virus to alpha/beta interferon and to gamma interferon.

Authors:  D Moskophidis; M Battegay; M A Bruendler; E Laine; I Gresser; R M Zinkernagel
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

10.  Virus-induced immunosuppression: immune system-mediated destruction of virus-infected dendritic cells results in generalized immune suppression.

Authors:  P Borrow; C F Evans; M B Oldstone
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103
View more
  48 in total

Review 1.  Laboratory Diagnosis of Lassa Fever.

Authors:  Vanessa Raabe; Jeffrey Koehler
Journal:  J Clin Microbiol       Date:  2017-04-12       Impact factor: 5.948

2.  Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates.

Authors:  Igor S Lukashevich; Ricardo Carrion; Maria S Salvato; Keith Mansfield; Kathleen Brasky; Juan Zapata; Cristiana Cairo; Marco Goicochea; Gia E Hoosien; Anysha Ticer; Joseph Bryant; Harry Davis; Rasha Hammamieh; Maria Mayda; Marti Jett; Jean Patterson
Journal:  Vaccine       Date:  2008-08-08       Impact factor: 3.641

3.  Genomic profiling of host responses to Lassa virus: therapeutic potential from primate to man.

Authors:  Juan C Zapata; Maria S Salvato
Journal:  Future Virol       Date:  2015-03-13       Impact factor: 1.831

4.  Protection From Lethal Lassa Disease Can Be Achieved Both Before and After Virus Exposure by Administration of Single-Cycle Replicating Lassa Virus Replicon Particles.

Authors:  Markus H Kainulainen; Jessica R Spengler; Stephen R Welch; JoAnn D Coleman-McCray; Jessica R Harmon; Florine E M Scholte; Cynthia S Goldsmith; Stuart T Nichol; César G Albariño; Christina F Spiropoulou
Journal:  J Infect Dis       Date:  2019-09-13       Impact factor: 5.226

5.  Arenavirus Genome Rearrangement for the Development of Live Attenuated Vaccines.

Authors:  Benson Yee Hin Cheng; Emilio Ortiz-Riaño; Juan Carlos de la Torre; Luis Martínez-Sobrido
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

6.  Development of live-attenuated arenavirus vaccines based on codon deoptimization.

Authors:  Benson Yee Hin Cheng; Emilio Ortiz-Riaño; Aitor Nogales; Juan Carlos de la Torre; Luis Martínez-Sobrido
Journal:  J Virol       Date:  2015-01-14       Impact factor: 5.103

Review 7.  VaxCelerate II: rapid development of a self-assembling vaccine for Lassa fever.

Authors:  Pierre Leblanc; Leonard Moise; Cybelle Luza; Kanawat Chantaralawan; Lynchy Lezeau; Jianping Yuan; Mary Field; Daniel Richer; Christine Boyle; William D Martin; Jordan B Fishman; Eric A Berg; David Baker; Brandon Zeigler; Dale E Mais; William Taylor; Russell Coleman; H Shaw Warren; Jeffrey A Gelfand; Anne S De Groot; Timothy Brauns; Mark C Poznansky
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

8.  Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys.

Authors:  Sylvain Baize; Philippe Marianneau; Philippe Loth; Stéphanie Reynard; Alexandra Journeaux; Michèle Chevallier; Noël Tordo; Vincent Deubel; Hugues Contamin
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

9.  Vaccine Platforms to Control Arenaviral Hemorrhagic Fevers.

Authors:  Ricardo Carrion; Peter Bredenbeek; Xiaohong Jiang; Irina Tretyakova; Peter Pushko; Igor S Lukashevich
Journal:  J Vaccines Vaccin       Date:  2012-11-20

Review 10.  Comparative pathogenesis and systems biology for biodefense virus vaccine development.

Authors:  Gavin C Bowick; Alan D T Barrett
Journal:  J Biomed Biotechnol       Date:  2010-06-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.